¸Þ´º ¹Ù·Î°¡±â º»¹® ¹Ù·Î°¡±â
Å©°Ô±ÛÀÚ Å©±âÀÛ°ÔÇÁ¸°Æ®
Home  > Áø·á¾È³» > Áø·á°ú/ÀÇ·áÁø > Áø·á°ú¾È³»

Áø·á°ú¾È³»

»êºÎÀΰú

³í¹®
<³í¹®>
1. A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of a far infrared-emitting sericite belt in patients with primary dysmenorrhea. Complement Ther Med, 19(4):187-93, 2011.
2. Cyclooxygenase-2 is an independent predictor of poor prognosis in uterine leiomyosarcomas. Int J Gynecol Cancer, 21(4): 668-72, 2011.
3. Persistent chemical peritonitis resulting from spontaneous rupture of an ovarian mature cystic teratoma. Korean J Obstet Gynecol, 54(11): 726-30, 2011.
4. Diastolic forward flow in the fetal main pulmonary artery and its implication for fetal cardiac cycle evaluation. J Perinat Med, 39(4): 445-50, 2011.
5. P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. Oncol Res, 18(9): 453-9, 2010.
6. Appendectomy for patients presenting with epithelial ovarian cancer apparently confined to the pelvis: to do or not to do? J Womens Med, 3(1): 3-6, 2010.
7. Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol, 27(30): 5088-93, 2009.
8. Expression of MMP-2, MMP-9, and urokinase-type plasminogen activator in cervical intraepithelial neoplasia. Ann N Y Acad Sci, 1171: 100-4, 2009.
9. Clinical approach of hereditary cancer in gynecology. Korean J Obstet Gynecol, 52(1): 1-16, 2009.
10. NF-kappaB as a potential molecular target for cancer therapy. Biofactors, 29(1): 19-35, 2007.
Àú¼­